San Antonio, Texas USA (UroToday.com) Simpa Salami, University of Michigan, discussed circulating tumor cells (CTC) in localized prostate. There is a potential to extend research beyond CTC numeration and the objective of this study was to assess CTC significance in high risk prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
CTC counts were correlated with biochemical recurrence (BCR) using the Fisher’s exact test. Serum samples underwent slide preparation, cell staining, scanning, biomarker analysis and were correlated with pathology. CTCs were detected in 65% v 58% radical prostatectomy (RP) and radiotherapy (XRT) patients, respectively. BCR occurred more frequently in the RP versus XRT group 14/26 v 1/19, respectively. >2.5 CTC/ml was significantly associated with BCR. High AR protein, unique CK and nuclear size were significantly associated with BCR. Multidimensional classifier used in the RP cohort had a 33% and 95% sensitivity and specificity at predicting progression free survival. Therefore, characterization of CTCs may provide additional prognostic information beyond numeration alone. At our institution, we are assessing the utility of this and other biomarkers in detecting biochemical recurrence but equally important are further cost-effectiveness research discerning which biomarker detection is most appropriate with the highest sensitivity and specificity at improving the survival of our patients.
Presented By: Simpa Salami, University of Michigan
Written By: Stephen B. Williams, MD and Ashish M. Kamat
17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA